Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25968
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPatel, Oneel-
dc.contributor.authorChinni, Vidyasagar-
dc.contributor.authorEl Khoury, John-
dc.contributor.authorPerera, Marlon-
dc.contributor.authorNeto, Ary Serpa-
dc.contributor.authorMcDonald, Christine F-
dc.contributor.authorSee, Emily J-
dc.contributor.authorJones, Daryl A-
dc.contributor.authorBolton, Damien M-
dc.contributor.authorBellomo, Rinaldo-
dc.contributor.authorTrubiano, Jason A-
dc.contributor.authorIschia, Joseph J-
dc.date2021-05-
dc.date.accessioned2021-03-03T21:49:55Z-
dc.date.available2021-03-03T21:49:55Z-
dc.date.issued2021-02-25-
dc.identifier.citationJournal of Medical Virology 2021; 93(5): 3261-3267en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/25968-
dc.description.abstractZinc inhibits replication of the SARS-CoV virus. We aimed to evaluate the safety, feasibility and biological effect of administering high-dose intravenous zinc (HDIVZn) to patients with COVID-19. We performed a phase IIa double-blind, randomised controlled trial to compare HDIVZn to placebo in hospitalised patients with COVID-19. We administered trial treatment once daily for a maximum of seven days until either death or hospital discharge. We measured zinc concentration at baseline and during treatment and observed patients for any significant side effects. For eligible patients, we randomised and administered treatment to 33 adult participants to either HDIVZn (n=15) or placebo (n=18). We observed no serious adverse events throughout the study for a total of 94 HDIVZn administrations. However, 3 participants in the HDIVZn group reported infusion site irritation. Mean serum zinc on day 1 in the placebo, and the HDIVZn group was 6.9 ± 1.1 and 7.7 ± 1.6 µmol/l, respectively, consistent with zinc deficiency. HDIVZn, but not placebo, increased serum zinc levels above the deficiency cut off of 10.7 µmol/l (P<0.001) by day 6. Our study did not reach its target enrolment because stringent public health measures markedly reduced patient hospitalisations. Hospitalised COVID-19 patients demonstrated zinc deficiency. This can be corrected with HDIVZn. Such treatment appears safe, feasible and only associated with minimal peripheral infusion site irritation. This pilot study justifies further investigation of this treatment in COVID-19 patients. This article is protected by copyright. All rights reserved.en
dc.language.isoeng
dc.subjectCOVID-19en
dc.subjectrandomised controlled trialen
dc.subjecttrial protocolen
dc.subjectzincen
dc.titleA pilot double-blind safety and feasibility randomised controlled trial of high-dose intravenous zinc in hospitalised COVID-19 patients.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Medical Virologyen
dc.identifier.affiliationUrologyen
dc.identifier.affiliationRespiratory and Sleep Medicineen
dc.identifier.affiliationAustralian and New Zealand Intensive Care-Research Centre (ANZIC-RC), Monash University, Victoria, Australiaen
dc.identifier.affiliationCentre for Integrated Critical Care, The University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationInfectious Diseasesen
dc.identifier.affiliationSurgery (University of Melbourne)en
dc.identifier.affiliationIntensive Careen
dc.identifier.doi10.1002/jmv.26895en
dc.type.contentTexten
dc.identifier.orcid0000-0001-5628-7205en
dc.identifier.pubmedid33629384
Appears in Collections:Journal articles
Show simple item record

Page view(s)

24
checked on Jun 24, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.